Skip to main content
SpringerLink
Log in

Management of Humoral Primary Immunodeficiencies in Pediatrics

  • Chapter
  • First Online:
Book cover Humoral Primary Immunodeficiencies

Part of the book series: Rare Diseases of the Immune System ((RDIS))

  • 759 Accesses

Abstract

Children affected by humoral immunodeficiencies need a multidisciplinary medical approach. Immunoglobulin replacement therapy has a crucial role. In the last decades, subcutaneous immunoglobulin treatment has drastically changed patients’ quality of life. Many other strategies that contribute to a global management of the disease have to be applied. Respiratory physiotherapy represents the other pillar of the care of these patients. Optimal management also includes prevention strategies in order to avoid systemic complications. Treatment needs to be coordinated with a defined follow-up schedule in a pediatric immunology center. The follow-up should be in line with current recommendations but, at the same time, tailored to the needs of the specific patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 1999;92:34–48.

    Article  CAS  PubMed  Google Scholar 

  2. Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med. 1993;86:31–42.

    CAS  PubMed  Google Scholar 

  3. Quinti I, Soresina A, Spadaro G, Italian Primary Immunodeficiency Network, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27(3):308–16.

    Article  PubMed  Google Scholar 

  4. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bonilla FA, Bernstein IL, Khan DA, et al American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 Suppl. 1):S1–S63.

    Article  PubMed  Google Scholar 

  6. Abolhassani H, Aghamohammadi A, Abolhassani F, Eftekhar H, Heidarnia M, Rezaei N. Health policy for common variable immunodeficiency: burden of the disease. J Investig Allergol Clin Immunol. 2011;21(6):454–8.

    CAS  PubMed  Google Scholar 

  7. Busse PJ, Razvi S. Cunningham-Rundles C Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109(6):1001–4.

    Article  CAS  PubMed  Google Scholar 

  8. Björkander J, Wadsworth C, Hanson LA. 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes. Infection. 1985;13:102–10.

    Article  PubMed  Google Scholar 

  9. de Gracia J, Vendrell M, Alvarez A, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol. 2004;4(6):745–53.

    Article  PubMed  CAS  Google Scholar 

  10. Pourpak Z, Aghamohammadi A, Sedighipour L, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006;39:114–20.

    CAS  PubMed  Google Scholar 

  11. Ludvigsson JF, Neovius M, Hammarström L. Association between IgA deficiency & other autoimmune conditions: a population-based matched cohort study. J Clin Immunol. 2014;34:444–51.

    Article  CAS  PubMed  Google Scholar 

  12. Selective IgA deficiency Diagnostic and therapeutic recommendations Working group Associazione Italiana di Ematologia ed Oncologia pediatrica (AIEOP)-Italian primary immunodeficiencies network (IPINET) 16th December 2010.

    Google Scholar 

  13. Aghamohammadi A, Mohammadi J, Parvaneh N, Rezaei N, Moin M, Espanol T, Hammarstrom L. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol. 2008;147:87–92.

    Article  CAS  PubMed  Google Scholar 

  14. Erkoçoğlu M, Metin A, Kaya A, Özcan C, Akan A, Civelek E, Çapanoğlu M, Giniş T, Kocabaş CN. Allergic and autoimmune disorders in families with selective IgA deficiency. Turk J Med Sci. 2017;47:592–8.

    Article  PubMed  CAS  Google Scholar 

  15. Jorgensen GH, Gardulf A, Sigurdsson MI, Sigurdardottir ST, Thorsteinsdottir I, Gudmundsson S, Hammarström L, Ludviksson BR. Clinical symptoms in adults with selective IgA deficiency: a case-control study. J Clin Immunol. 2013;33:742–7.

    Article  CAS  PubMed  Google Scholar 

  16. Yazdani R, Azizi G, Abolhassani H, Aghamohammadi A. Selective IgA deficiency: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management. Scand J Immunol. 2017;85:3–12.

    Article  CAS  PubMed  Google Scholar 

  17. CDC. Vaccination of persons with primary and secondary immune deficiencies. https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/immuno-table.pdf. Accessed 16 March 2018.

  18. Sthiem ER, Ochs HD, Winkelstein JA. Immunologic disorders in infants and children. 5th ed. Philadelphia: Elsevier Saunders.

    Google Scholar 

  19. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–8.

    CAS  PubMed  Google Scholar 

  20. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Bio Drugs. 2007;21:105–16.

    CAS  Google Scholar 

  21. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114–21.

    Article  CAS  PubMed  Google Scholar 

  22. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–73.

    Article  CAS  PubMed  Google Scholar 

  23. Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011;7:301–16.

    Article  CAS  PubMed  Google Scholar 

  24. Weiler CR. Immunoglobulin therapy: history, indications, and routes of administration. Int J Dermatol. 2004;43:163–6.

    Article  CAS  PubMed  Google Scholar 

  25. Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006;26:813–27.

    Article  CAS  PubMed  Google Scholar 

  26. Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135:255–63.

    Article  CAS  PubMed  Google Scholar 

  27. Orange JS, Hossny EM, Weiler CR, Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(Suppl. 4):S525–53.

    Article  CAS  PubMed  Google Scholar 

  28. Eijkhout HW, van Der Meer JW, Kallenberg CG, Inter-University Working Party for the Study of Immune Deficiencies, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135:165–74.

    Article  CAS  PubMed  Google Scholar 

  29. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114–21. quiz 122

    Article  CAS  PubMed  Google Scholar 

  30. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94–100.

    Article  CAS  PubMed  Google Scholar 

  31. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32:1180–92.

    Article  CAS  PubMed  Google Scholar 

  32. Berger M, Flebogamma 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27:628–33.

    Article  PubMed  Google Scholar 

  33. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122:210–2.

    Article  CAS  PubMed  Google Scholar 

  34. Ballow M. Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data. Ann Allergy Asthma Immunol. 2013;111(6 Suppl):S2–5.

    Article  CAS  PubMed  Google Scholar 

  35. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.

    Article  CAS  PubMed  Google Scholar 

  36. Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, Berger M. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179(2):146–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19:139–45.

    CAS  PubMed  Google Scholar 

  38. Aghamohammadi A, Farhoudi A, Nikzad M, et al. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann Allergy Asthma Immunol. 2004;92:60–4.

    Article  CAS  PubMed  Google Scholar 

  39. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.

    Article  CAS  PubMed  Google Scholar 

  40. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:434–42.

    Article  PubMed  Google Scholar 

  41. Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol. 2002;104:237–41.

    Article  CAS  PubMed  Google Scholar 

  42. Gustafson R, Gardulf A, et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol. 2008;152:274–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy. 2017;9:1035–50.

    Article  CAS  PubMed  Google Scholar 

  44. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010;30:301–7.

    Article  CAS  PubMed  Google Scholar 

  45. Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol. 2013;111:51–5.

    Article  CAS  PubMed  Google Scholar 

  46. Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr Allergy Immunol. 2013;24:49–53.

    Article  PubMed  Google Scholar 

  47. Urschel S, Kayikci L, Wintergerst U, Notheis G, Jansson A, Belohradsky BH. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J Pediatr. 2009;154:888–94.

    Article  PubMed  Google Scholar 

  48. Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, Claudio P, Franco D, Maria Pesce A, Borghese F, Guerra A, Rondelli R, Plebani A, Network IPI. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27:308–16.

    Article  PubMed  Google Scholar 

  49. Lindberg K, Gustafson R, Samuelson A, Rynnel-Dagöö B. Impact of IgG replacement therapy and antibiotic treatment on the colonization of non-encapsulated Haemophilus influenzae in the nasopharynx in patients with hypogammaglobulinaemia. Scand J Infect Dis. 2001;33:904–8.

    Article  CAS  PubMed  Google Scholar 

  50. Sewell WA, Buckland M, Jolles SR. Therapeutic strategies in common variable immunodeficiency. Drugs. 2003;63:1359–71.

    Article  PubMed  Google Scholar 

  51. López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol. 2008;8:286–91.

    Article  PubMed  CAS  Google Scholar 

  52. Resti M, Micheli A, Moriondo M, Becciolini L, Cortimiglia M, Canessa C, Indolfi G, Bartolini E, de Martino M, Azzari C. Comparison of the effect of antibiotic treatment on the possibility of diagnosing invasive pneumococcal disease by culture or molecular methods: a prospective, observational study of children and adolescents with proven pneumococcal infection. Clin Ther. 2009;31:1266–73.

    Article  CAS  PubMed  Google Scholar 

  53. Azzari C, Moriondo M, Indolfi G, Massai C, Becciolini L, de Martino M, Resti M. Molecular detection methods and serotyping performed directly on clinical samples improve diagnostic sensitivity and reveal increased incidence of invasive disease by Streptococcus pneumoniae in Italian children. J Med Microbiol. 2008;57:1205–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Common Variable Immunodeficiency Diagnostic and therapeutic recommendations Working group Associazione Italiana di Ematologia ed Oncologia pediatrica (AIEOP)-Italian primary immunodeficiencies network (IPINET) december 2001.

    Google Scholar 

  55. Aghamohammadi A, Abolhassani H, Moazzami K, Parvaneh N, Rezaei N. Correlation between common variable immunodeficiency clinical phenotypes and parental consanguinity in children and adults. J Investig Allergol Clin Immunol. 2010;20(5):372–9.

    CAS  PubMed  Google Scholar 

  56. Hampson FA, Chandra A, Screaton NJ, et al. Respiratory disease in common variable immunodeficiency and other primary immunodeficiency disorders. Clin Radiol. 2012;67:587–95.

    Article  CAS  PubMed  Google Scholar 

  57. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372:489–502.

    Article  PubMed  Google Scholar 

  58. Garrod R, Lasserson T. Role of physiotherapy in the management of chronic lung diseases: an overview of systematic reviews. Respir Med. 2007;101:2429–36.

    Article  PubMed  Google Scholar 

  59. Bradley J, Moran F, Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev. 2002;3:CD002166.

    Google Scholar 

  60. Aghamohammadi A, Moin M, Kouhi A, et al. Chromosomal radiosensitivity in patients with common variable immunodeficiency. Immunobiology. 2008;213:447–54.

    Article  CAS  PubMed  Google Scholar 

  61. Palanduz S, Palanduz A, Yalcin I, et al. In vitro chromosomal radiosensitivity in common variable immune deficiency. Clin Immunol Immunopathol. 1998;86:180–2.

    Article  CAS  PubMed  Google Scholar 

  62. Vorechovský I, Scott D, Haeney MR, Webster DA. Chromosomal radiosensitivity in common variable immune deficiency. Mutat Res. 1993;290:255–64.

    Article  PubMed  Google Scholar 

  63. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22:396–414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Touw CM, van de Ven AA, de Jong PA, et al. Detection of pulmonary complications in common variable immunodeficiency. Pediatr Allergy Immunol. 2010;21:793–805.

    Article  PubMed  Google Scholar 

  65. Busse PJ, Farzan S, Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol. 2007;98:1–8. quiz 8

    Article  CAS  PubMed  Google Scholar 

  66. Yalçin E, Kiper N, Ozçelik U, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006;31:49–55.

    Article  PubMed  Google Scholar 

  67. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J. 1997;10(5):994–9.

    Article  CAS  PubMed  Google Scholar 

  68. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med. 2005;4:117–22.

    Article  CAS  PubMed  Google Scholar 

  69. Lin HC, Cheng HF, Wang CH, Liu CY, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med. 1997;155:2024–9.

    Article  CAS  PubMed  Google Scholar 

  70. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60:239–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 1987;19:831–8.

    Article  CAS  PubMed  Google Scholar 

  72. Chuchalin A, Csiszér E, Gyurkovics K, et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs. 2007;9.(Suppl. 1:21–31.

    Article  PubMed  Google Scholar 

  73. Corless JA, Warburton CJ. Surgery vs non-surgical treatment for bronchiectasis. Cochrane Database Syst Rev. 2000;4:CD002180.

    Google Scholar 

  74. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998;113:1329–34.

    Article  PubMed  Google Scholar 

  75. Quartier P, Debré M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134:589–96.

    Article  CAS  PubMed  Google Scholar 

  76. Foruny JR, Bárcena R, Moreno A, et al. Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization. Transplantation. 2006;82:289–90.

    Article  PubMed  Google Scholar 

  77. Cunningham-Rundles C, Bodian C, Ochs HD, Martin S, Reiter-Wong M, Zhuo Z. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol. 2001;100:181–90.

    Article  CAS  PubMed  Google Scholar 

  78. Rump JA, Jahreis A, Schlesier M, Stecher S, Peter HH. A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 1997;110:167–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Ten RM, Anderson PM, Zein NN, Temesgen Z, Clawson ML, Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol. 2002;2:333–44.

    Article  CAS  PubMed  Google Scholar 

  80. Franco F, Sheikh A, Greenstone M. Short acting beta-2 agonists for bronchiectasis. Cochrane Database Syst Rev. 2003;3:CD003572.

    Google Scholar 

  81. Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev. 2001;4:CD002155.

    Google Scholar 

  82. Abolhassani H, Sagvand BT, Shokuhfar T, Mirminachi B, Rezaei N, Aghamohammadi A. A review on guidelines for management and treatment of common variable immunodeficiency. Expert Rev Clin Immunol. 2013;9(6):561–75.

    Article  CAS  PubMed  Google Scholar 

  83. Davies CW, Juniper MC, Gray W, Gleeson FV, Chapel HM, Davies RJ. Lymphoid interstitial pneumonitis associated with common variable hypogammaglobulinaemia treated with cyclosporin A. Thorax. 2000;55:88–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med. 2008;102:1–9.

    Article  PubMed  Google Scholar 

  85. Boursiquot JN, Gérard L, Malphettes M, et al; DEFI Study Group. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol. 2013;33:84–95.

    Article  CAS  PubMed  Google Scholar 

  86. Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med. 2003;2:311–20.

    Article  CAS  PubMed  Google Scholar 

  87. Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA—evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006;2:458–9.

    Article  PubMed  Google Scholar 

  88. Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5:156–9.

    Article  CAS  PubMed  Google Scholar 

  89. Paramothayan S, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2006;3:CD003536.

    Google Scholar 

  90. Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-alpha receptor fusion protein. Br J Dermatol. 2001;144:597–600.

    Article  CAS  PubMed  Google Scholar 

  91. Fernández-Ruiz M, Guerra-Vales JM, Francisco-Javier CF, et al. Fever of unknown origin in a patient with common variable immunodeficiency associated with multisystemic granulomatous disease. Intern Med. 2007;46:1197–202.

    Article  PubMed  Google Scholar 

  92. Hatab AZ, Ballas ZK. Caseating granulomatous disease in common variable immunodeficiency treated with infliximab. J Allergy Clin Immunol. 2005;116:1161–2.

    Article  CAS  PubMed  Google Scholar 

  93. Baughman RP, Drent M, Kavuru M, et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.

    Article  CAS  PubMed  Google Scholar 

  94. Thatayatikom A, Thatayatikom S, White AJ. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol. 2005;95:293–300.

    Article  PubMed  Google Scholar 

  95. Martínez García MA, de Rojas MD, Nauffal Manzur MD, et al. Respiratory disorders in common variable immunodeficiency. Respir Med. 2001;95:191–5.

    Article  PubMed  Google Scholar 

  96. Sève P, Bourdillon L, Sarrot-Reynauld F, DEF-I Study Group, et al. Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients. Medicine (Baltimore). 2008;87:177–84.

    Article  Google Scholar 

  97. Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore). 2004;83:254–63.

    Article  CAS  Google Scholar 

  98. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145:709–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol. 2008;28.(Suppl. 1:S42–5.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Wakim M, Shah A, Arndt PA, et al. Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency. Am J Hematol. 2004;76:152–5.

    Article  PubMed  Google Scholar 

  101. Nos P, Bastida G, Beltran B, Aguas M, Ponce J. Crohn’s disease in common variable immunodeficiency: treatment with antitumor necrosis factor alpha. Am J Gastroenterol. 2006;101:2165–6.

    Article  PubMed  Google Scholar 

  102. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood. 2010;116:7–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Shillitoe B, Gennery A. X-Linked Agammaglobulinaemia: Outcomes in the modern era. Clin Immunol. 2017;183:54–62.

    Article  CAS  PubMed  Google Scholar 

  104. Chua I, Standish R, Lear S, et al. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 2007;150:306–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Agarwal S, Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep. 2009;9:347–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol. 2007;31:1800–12.

    Article  PubMed  Google Scholar 

  107. Raeiszadeh M, Kopycinski J, Paston SJ, et al. The T cell response to persistent herpes virus infections in common variable immunodeficiency. Clin Exp Immunol. 2006;146:234–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Abolhassani H, Aghamohammadi A, Imanzadeh A, Mohammadinejad P, Sadeghi B, Rezaei N. Malignancy phenotype in common variable immunodeficiency. J Investig Allergol Clin Immunol. 2012;22:133–4.

    CAS  PubMed  Google Scholar 

  109. Gompels MM, Hodges E, Lock RJ, et al. Associated Study Group. Lymphoproliferative disease in antibody deficiency: a multi-centre study. Clin Exp Immunol. 2003;134:314–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Ochtrop ML, Goldacker S, May AM, et al. T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. Blood. 2011;118:309–18.

    Article  CAS  PubMed  Google Scholar 

  111. Rizzi M, Neumann C, Fielding AK, et al. Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. J Allergy Clin Immunol. 2011;128:1371–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paediatric Immunology Department, Meyer Children’s Hospital, Florence, Italy

    Chiara Azzari & Clementina Canessa

Authors
  1. Chiara Azzari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clementina Canessa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clementina Canessa .

Editor information

Editors and Affiliations

  1. Careggi Hospital, Department of Clinical and Experimental Medicine, University of Florence, Firenze, Italy

    Mario Milco D'Elios

  2. University Medical Centre Freiburg, Department of Rheumatology and Clinical Immunology and Center for Chronic Immunodeficiency, Freiburg, Germany

    Marta Rizzi

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Azzari, C., Canessa, C. (2019). Management of Humoral Primary Immunodeficiencies in Pediatrics. In: D'Elios, M., Rizzi, M. (eds) Humoral Primary Immunodeficiencies. Rare Diseases of the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-319-91785-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91785-6_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91784-9

  • Online ISBN: 978-3-319-91785-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation